4-Hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidines: selective h5-HT1D agonists for the treatment of migraine |
| |
| Authors: | Bourrain S Neduvelil J G Beer M S Stanton J A Showell G A MacLeod A M |
| |
| Affiliation: | Merck, Sharp & Dohme Research Laboratories, Terlings Park, Harlow, UK. Sylvie Bourrain@Merck.com |
| |
| Abstract: | A series of 4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl] piperidines was investigated as potential selective h5-HT1D agonists for the treatment of migraine. The 4-[(N-benzyl-N-methyl)amino]methyl analog 12a was found to be a full agonist at the h5-HT1D receptor with good binding selectivity over the h5-HT1B receptor. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
